PT -期刊文章盟克里斯蒂娜•雷默AU -拉娅格劳盟-皮拉尔金盟Lluis Ramio AU -路易斯Brieva盟-阿尔伯特Saiz盟-安东尼奥诺盟-奥尔加·卡非盟- Eva Martinez-Caceres AU -琼哥TI -多中心,双盲随机临床和MRI研究大剂量口服和静脉注射甲基强的松龙在急性复发的多发性硬化症(P01.128) DP - 2012年4月23日TA -神经病学PG - P01.128 P01.128 VI - 78 IP - 1补充4099 - //www.ez-admanager.com/content/78/1_Supplement/P01.128.short 4100 - //www.ez-admanager.com/content/78/1_Supplement/P01.128.full所以Neurology2012 4月23日;首页78 AB -目的:比较临床和放射疗效、耐受性和安全性的四甲基强的松龙(ivMP)和口服甲强龙(oMP)等效高剂量在多发性硬化(MS)患者经历了最近的一次复发。背景bioequivalent剂量的oMP不是效果低于ivMP女士复发。设计/方法:49女士和中度或重度患者近期临床复发被随机分配接受1000毫克/天/ 3天的ivMP (n = 24)或1250毫克/天/天oMP (n = 25)及其匹配的安慰剂,double-dummy。扩大残疾状态量表(eds)基线和周1、4和12,大脑核磁共振在基线和周1和4进行了评估。主要终点是比较临床(eds)和放射(RM) 2路线的功效降低T1-Gd-enhancing eds得分和数量和体积的病变,新的或更大的DP / T2病灶和黑洞从治疗4周后启动。二次结果安全、耐受性和生活质量档案的管理上的路线。所有结果都意图/协议(IPP)。结果:有一个eds改进ivMP和oMP: 1.1(0.7, 1.5)和1.1(0.7,1.5)在4周(术中,0.001)。不同群体间的基线调整为0.0 [-0.5,0.6]p = 0.889。ivMP之间没有差异数量和oMP Gd-enhancing病变(0(0 - 1)和0 0;0.5,p = 0.630); volume Gd-enhancing (0[0-88.0] vs 0[0-32.9] mm3, p=0.735); next or bigger DP/T2 lesions (0[0-194] vs 0[0-123], p=0.769); and black holes (0[0-0] vs 0[0-0], p=0.344). Both treatments were well-tolerated, and no serious adverse event was reported.Conclusions: This study shows that 1250 mg oMP/3days is not inferior to 1000 mg ivMP/3 days in reducing EDSS score and MRI lesions at 4 weeks. MP was equally safe in both groups. These results support the use of oMP –instead of ivMP- for MS relapses, due to patients' convenience and lower cost.Supported by: Ministry of Health (EC07/90278), Biogen Idec.Disclosure: Dr. Ramo has nothing to disclose. Dr. Grau has nothing to disclose. Dr. Giner has nothing to disclose. Dr. Ramio has nothing to disclose. Dr. Brieva has nothing to disclose. Dr. Saiz has nothing to disclose. Dr. Cano has nothing to disclose. Dr. Carmona has nothing to disclose. Dr. Martínez-Cáceres has nothing to disclose. Dr. Costa has nothing to disclose.Monday, April 23 2012, 14:00 pm-18:30 pm